Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Amivantamab in patients with EGFR Ex20ins-mutated NSCLCПодробнее

Amivantamab in patients with EGFR Ex20ins-mutated NSCLC

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLCПодробнее

Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLCПодробнее

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC

Amivantamab and Mobocertinib for EGFR Exon-20 Disease - Lung Cancer Video LibraryПодробнее

Amivantamab and Mobocertinib for EGFR Exon-20 Disease - Lung Cancer Video Library

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLCПодробнее

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicityПодробнее

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLCПодробнее

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLC

ASCO 2021 Lung: Amivantamab + Lazertinib in EGFR, Patritumab Deruxtecan in EGFR+ Acquired ResistanceПодробнее

ASCO 2021 Lung: Amivantamab + Lazertinib in EGFR, Patritumab Deruxtecan in EGFR+ Acquired Resistance

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20Подробнее

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20

From clinic to practice in NSCLC patients with exon 20 mutationsПодробнее

From clinic to practice in NSCLC patients with exon 20 mutations

Amivantamab and Mobocertinib: Side Effects and Treatment Timing - Lung CancerПодробнее

Amivantamab and Mobocertinib: Side Effects and Treatment Timing - Lung Cancer

PAPILLON Phase III primary results: amivantamab + chemo vs chemo in EGFR Exon 20 NSCLCПодробнее

PAPILLON Phase III primary results: amivantamab + chemo vs chemo in EGFR Exon 20 NSCLC

Amivantamab Plus Lazertinib for EGFR-Mutant Lung Cancer Following Progression on OsimertinibПодробнее

Amivantamab Plus Lazertinib for EGFR-Mutant Lung Cancer Following Progression on Osimertinib

Amivantamab and Lazertinib in EGFR MET+ Disease - 2022 Program: Targeted Therapies Forum - EnglishПодробнее

Amivantamab and Lazertinib in EGFR MET+ Disease - 2022 Program: Targeted Therapies Forum - English

Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLCПодробнее

Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLC

Update from CHRYSALIS: amivantamab in patients with NSCLC with MET exon 14 skipping mutationПодробнее

Update from CHRYSALIS: amivantamab in patients with NSCLC with MET exon 14 skipping mutation

CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLCПодробнее

CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLC

Q&A: What is the Efficacy of Amivantamab and Lazertinib? - Targeted Therapies in Lung Cancer 2023Подробнее

Q&A: What is the Efficacy of Amivantamab and Lazertinib? - Targeted Therapies in Lung Cancer 2023

Dr Vashisth Maniar | Hidden EGFR Threat Role of AmivantamabПодробнее

Dr Vashisth Maniar | Hidden EGFR Threat Role of Amivantamab